CN1650868A - Compound medicinal preparation for treating pneumonia infection disease and its preparation method - Google Patents
Compound medicinal preparation for treating pneumonia infection disease and its preparation method Download PDFInfo
- Publication number
- CN1650868A CN1650868A CN 200410081382 CN200410081382A CN1650868A CN 1650868 A CN1650868 A CN 1650868A CN 200410081382 CN200410081382 CN 200410081382 CN 200410081382 A CN200410081382 A CN 200410081382A CN 1650868 A CN1650868 A CN 1650868A
- Authority
- CN
- China
- Prior art keywords
- compound medicinal
- hydrochloride
- cefixime
- medicinal formulation
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 38
- 150000001875 compounds Chemical class 0.000 title claims description 19
- 208000015181 infectious disease Diseases 0.000 title claims description 12
- 206010035664 Pneumonia Diseases 0.000 title claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 9
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 claims abstract description 47
- 229960000985 ambroxol hydrochloride Drugs 0.000 claims abstract description 47
- 229960002129 cefixime Drugs 0.000 claims abstract description 42
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 claims abstract description 42
- NZQJSIPYDOTDFS-JJHIVTNASA-M sodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C([O-])=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 NZQJSIPYDOTDFS-JJHIVTNASA-M 0.000 claims abstract description 16
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 239000003826 tablet Substances 0.000 claims abstract description 5
- 239000000725 suspension Substances 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 33
- DASYMCLQENWCJG-XUKDPADISA-N cefetamet pivoxil Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(=O)OCOC(=O)C(C)(C)C)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DASYMCLQENWCJG-XUKDPADISA-N 0.000 claims description 25
- 229950000726 cefetamet pivoxil Drugs 0.000 claims description 20
- 238000009472 formulation Methods 0.000 claims description 18
- 239000008187 granular material Substances 0.000 claims description 14
- 239000003242 anti bacterial agent Substances 0.000 claims description 9
- 229940088710 antibiotic agent Drugs 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000007910 chewable tablet Substances 0.000 claims description 4
- 229940068682 chewable tablet Drugs 0.000 claims description 4
- 239000007919 dispersible tablet Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000003607 modifier Substances 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000006184 cosolvent Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- MQLRYUCJDNBWMV-GHXIOONMSA-N cefetamet Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 MQLRYUCJDNBWMV-GHXIOONMSA-N 0.000 abstract description 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 description 28
- 235000019698 starch Nutrition 0.000 description 28
- 239000008107 starch Substances 0.000 description 28
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 24
- 239000002002 slurry Substances 0.000 description 16
- 229960005174 ambroxol Drugs 0.000 description 15
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 15
- 238000005516 engineering process Methods 0.000 description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 12
- 235000019359 magnesium stearate Nutrition 0.000 description 12
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 12
- 239000008108 microcrystalline cellulose Substances 0.000 description 12
- 229940016286 microcrystalline cellulose Drugs 0.000 description 12
- 238000005303 weighing Methods 0.000 description 12
- 206010013786 Dry skin Diseases 0.000 description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 10
- 229930006000 Sucrose Natural products 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- 239000007779 soft material Substances 0.000 description 10
- 239000005720 sucrose Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229960004793 sucrose Drugs 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 239000004141 Sodium laurylsulphate Substances 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229930186147 Cephalosporin Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 229960004041 cefetamet Drugs 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
A medicine in the form of tablet, capsule, particle, oral liquid, or suspension for treating pulmonary infectious diseases is prepared from ambroxol hydrochloride and one of cefixime, cefetamet sodium and cefetamet hydrochloride.
Description
Technical field:
The present invention relates to a kind of anti-infective compound medicinal formulation and preparation method thereof, concrete, the present invention relates to a kind of compound medicinal formulation for the treatment of pneumonia infection disease and preparation method thereof.
Background technology:
Pneumonia infection disease is one of common respiratory tract infection illness.Because characteristics such as cephalo-type antibiotics are stable to beta-lactamase, has has a broad antifungal spectrum, and bactericidal action is strong, therefore be usually used in treatment, the especially third generation cephalo-type antibiotics of respiratory tract infection illness clinically, as cefixime (Cefixime C
16H
15N
5O
7S
23H
2O), Ro 15-8074/001 (Cefetamet SodiumC
14H
14N
5NaO
5S
2), Cefetamet Pivoxil Hydrochloride (Cefetamet Pivoxil HydrochlorideC
14H
15N
5O
7S
2HCL) etc.But the sensitivity of microorganism to it is not only depended in the success of antibacterial therapy, but also closely related with the drug level of infection site.
So far as is known, ambroxol hydrochloride (Ambroxol Hydrochloride) is the phlegm dissolving agent of a new generation, it not only can increase the secretion of respiratory mucosa serous gland, reduce the mucous gland secretion, thereby reduce sputum viscosity, but also can promote the secretion of pulmonary surfactant, and increase the bronchus ciliary movement, make sputum be easy to expectoration.On this basis, discover through us, phlegm dissolving agent ambroxol hydrochloride can also increase the penetrance of cephalosporins such as cefixime, Ro 15-8074/001 and Cefetamet Pivoxil Hydrochloride to lung tissue, thereby improved the concentration of antibiotics greatly, but simultaneously the drug level in the blood plasma has not been had influence at infection sites such as lungs.
Current, be that cephalo-type preparation and ambroxol hydrochloride preparation are used as two kinds of compatibility of drugss clinically, because dose is big, dosage is not accurate enough, thereby causes its therapeutic effect to be affected.
Summary of the invention:
The object of the present invention is to provide a kind of compound medicinal formulation for the treatment of pneumonia infection disease.Said preparation not only can strengthen the antibacterial activity of infected pulmonary greatly, strengthens therapeutic effect, has also simultaneously that clinical practice is more convenient, taking dose is less relatively and characteristic of accurate.
Another object of the present invention is to provide the preparation method of this compound medicinal formulation.
The objective of the invention is that following technical scheme realizes by implementing.
A kind of compound medicinal formulation for the treatment of pneumonia infection disease is characterized in that it mainly is to be made by 1: 1～20 weight proportion by ambroxol hydrochloride and cephalo-type antibiotics active component.
The chemical structural formula of described ambroxol hydrochloride is as follows:
Ambroxol hydrochloride (Ambroxol Hydrochloride)
Described cephalo-type antibiotics is selected cefixime, Ro 15-8074/001 or Cefetamet Pivoxil Hydrochloride for use, and its chemical structural formula is as follows respectively:
Cefixime (Cefixime)
Ro 15-8074/001 (Cefetamet Sodium)
Cefetamet Pivoxil Hydrochloride (Cefetamet Pivoxil Hydrochloride)
The preferred weight proportioning of described ambroxol hydrochloride and Cefetamet Pivoxil Hydrochloride is 1: 1～8.
The preferred weight proportioning of described ambroxol hydrochloride and Ro 15-8074/001 is 1: 1～5.
Described compound medicinal formulation comprises peroral dosage forms such as tablet, dispersible tablet, chewable tablet, capsule, granule, oral liquid, dry suspension, and various injection, injectable sterile powder, freeze-dried powder etc.
Described compound medicinal formulation comprises adjuvant necessary on the galenic pharmacy, and the adjuvant of described necessity comprises the diluent of tablet, binding agent, disintegrating agent, lubricant, correctives, aromatic; The solvent of oral liquid, stabilizing agent, acid-base modifier; The cosolvent of injection, antioxidant, acid-base modifier.
Preparation method of the present invention is that active component and adjuvant are made various dosage forms by the universal method on the galenic pharmacy.
The invention has the advantages that:
1, ambroxol hydrochloride can increase the concentration of cephalosporin in pulmonary, thereby has brought into play the antibacterial action of cephalosporin to greatest extent.
2, after antibiotics such as ambroxol hydrochloride and cefixime, Ro 15-8074/001, Cefetamet Pivoxil Hydrochloride share, the action intensity of antibiotics was significantly improved, thereby has significantly improved the therapeutic effect to pneumonia infection disease.
3, compound medicinal formulation clinical practice of the present invention is convenient, taking dose is less relatively and accurate.
The specific embodiment:
Embodiment 1: the preparation of cefixime ambroxol sheet
Prescription:
Cefixime 100g
Ambroxol hydrochloride 60g
Starch 25g
Microcrystalline Cellulose 50g
The low hydroxypropyl cellulose 12.5g that gets
10% starch slurry 30ml
Magnesium stearate 2.5g
Make 1000
Preparation technology: take by weighing cefixime, ambroxol hydrochloride, starch, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose respectively by above-mentioned prescription, pulverize the back and cross 80 eye mesh screens, mix homogeneously, add 10% starch slurry system soft material, the wet grain of the 20 eye mesh screen systems of crossing, 50 ℃ of dryings 3 hours add magnesium stearate and cross 18 mesh sieve granulate, tabletting, every heavily about 0.25g.
Embodiment 2: the preparation of cefixime ambroxol dispersible tablet
Prescription:
Cefixime 100g
Ambroxol hydrochloride 60g
Lactose 37.5g
Microcrystalline Cellulose 36g
Crospolyvinylpyrrolidone 15g
10% polyvinylpyrrolidonesolution solution 30ml
Sodium lauryl sulphate 1.5g
Make 1000
Preparation technology: take by weighing cefixime, ambroxol hydrochloride, lactose, microcrystalline Cellulose, crospolyvinylpyrrolidone respectively by above-mentioned prescription, pulverize the back and cross 80 eye mesh screens, mix homogeneously, add 10% polyvinylpyrrolidonesolution solution system soft material, the wet grain of the 30 eye mesh screen systems of crossing, 50 ℃ of dryings 3 hours add sodium lauryl sulphate and cross 20 mesh sieve granulate, the heavily about 0.25g of tabletting, sheet.
Embodiment 3: the capsular preparation of cefixime ambroxol
Prescription:
Cefixime 100g
Ambroxol hydrochloride 60g
Starch 25g
Microcrystalline Cellulose 50g
The low hydroxypropyl cellulose 12.5g that gets
10% starch slurry 25ml
Magnesium stearate 2.5g
Make 1000
Preparation technology: take by weighing cefixime, ambroxol hydrochloride, starch, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose respectively by above-mentioned prescription, pulverize the back and cross 80 eye mesh screens, mix homogeneously, add 10% starch slurry system soft material, the wet grain of the 20 eye mesh screen systems of crossing, 50 ℃ of dryings 3 hours add magnesium stearate and cross 18 mesh sieve granulate, the heavily about 0.25g of filled capsules, capsule.
Embodiment 4: the preparation of cefixime ambroxol granule
Prescription:
Cefixime 100g
Ambroxol hydrochloride 60g
Sucrose 525g
Carboxymethyl starch sodium 495g
10% starch slurry 30ml
Essence 2ml
Make 1000 bags
Preparation technology: take by weighing cefixime, ambroxol hydrochloride, sucrose, carboxymethyl starch sodium respectively by above-mentioned prescription, pulverize the back and cross 80 eye mesh screens, mix homogeneously adds 10% starch slurry system soft material, the wet grain of the 20 eye mesh screen systems of crossing, 50 ℃ of dryings 3 hours, cross 18 mesh sieve granulate, spray into essence, mix homogeneously, packing, every bag of about 1.2g.
Embodiment 5: the preparation of cefixime ambroxol chewable tablet
Prescription:
Cefixime 100g
Ambroxol hydrochloride 60g
Sucrose 122g
Micropowder silica gel 15g
10% starch slurry 40ml
Essence 2ml
Magnesium stearate 3g
Make 1000
Preparation technology: take by weighing cefixime, ambroxol hydrochloride, sucrose respectively by above-mentioned prescription, pulverize the back and cross 80 eye mesh screens, mix homogeneously adds 10% starch slurry system soft material, the wet grain of the 20 mesh sieve systems of crossing, 50 ℃ of dryings 3 hours, add micropowder silica gel, magnesium stearate is crossed 18 mesh sieve granulate, sprays into essence, mix homogeneously, the heavily about 0.3g of tabletting, sheet.
Embodiment 6: the preparation of Ro-15-8075 ambroxol sheet
Prescription:
Cefetamet Pivoxil Hydrochloride 100g
Ambroxol hydrochloride 60g
Starch 25g
Microcrystalline Cellulose 50g
The low hydroxypropyl cellulose 12.5g that gets
10% starch slurry 30ml
Magnesium stearate 2.5g
Make 1000
Preparation technology: take by weighing Cefetamet Pivoxil Hydrochloride, ambroxol hydrochloride, starch, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose respectively by above-mentioned prescription, pulverize the back and cross 80 eye mesh screens, mix homogeneously, add 10% starch slurry system soft material, the wet grain of the 20 eye mesh screen systems of crossing, 50 ℃ of dryings 3 hours add magnesium stearate and cross 18 mesh sieve granulate, tabletting, every heavily about 0.25g.
Embodiment 7: the preparation of Ro-15-8075 ambroxol dispersible tablet
Prescription:
Cefetamet Pivoxil Hydrochloride 100g
Ambroxol hydrochloride 60g
Lactose 37g
Microcrystalline Cellulose 36g
Crospolyvinylpyrrolidone 15g
10% polyvinylpyrrolidonesolution solution 35ml
Sodium lauryl sulphate 1.5g
Make 1000
Preparation technology: take by weighing Cefetamet Pivoxil Hydrochloride, ambroxol hydrochloride, lactose, microcrystalline Cellulose, crospolyvinylpyrrolidone respectively by above-mentioned prescription, pulverize the back and cross 80 eye mesh screens, mix homogeneously, add 10% polyvinylpyrrolidonesolution solution system soft material, the wet grain of the 30 eye mesh screen systems of crossing, 50 ℃ of dryings 3 hours add sodium lauryl sulphate and cross 20 mesh sieve granulate, the heavily about 0.25g of tabletting, sheet.
Embodiment 8: the capsular preparation of Ro-15-8075 ambroxol
Prescription:
Cefetamet Pivoxil Hydrochloride 100g
Ambroxol hydrochloride 60g
Starch 25g
Microcrystalline Cellulose 50g
The low hydroxypropyl cellulose 12.5g that gets
10% starch slurry 30ml
Magnesium stearate 2.5g
Make 1000
Preparation technology: take by weighing Cefetamet Pivoxil Hydrochloride, ambroxol hydrochloride, starch, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose respectively by above-mentioned prescription, pulverize the back and cross 80 eye mesh screens, mix homogeneously, add 10% starch slurry system soft material, the wet grain of the 20 eye mesh screen systems of crossing, 50 ℃ of dryings 3 hours add magnesium stearate and cross 18 mesh sieve granulate, the heavily about 0.25g of filled capsules, capsule.
Embodiment 9: Ro-15-8075 ambroxol granule
Prescription:
Cefetamet Pivoxil Hydrochloride 100g
Ambroxol hydrochloride 60g
Sucrose 525g
Carboxymethyl starch sodium 495g
10% starch slurry 35ml
Essence 2ml
Make 1000 bags
Preparation technology: take by weighing Cefetamet Pivoxil Hydrochloride, ambroxol hydrochloride, sucrose, carboxymethyl starch sodium respectively by above-mentioned prescription, pulverize the back and cross 80 eye mesh screens, mix homogeneously adds 10% starch slurry system soft material, the wet grain of the 20 eye mesh screen systems of crossing, 50 ℃ of dryings 3 hours, cross 18 mesh sieve granulate, spray into essence, mix homogeneously, packing, every bag of about 1.2g.
Embodiment 10: Ro-15-8075 ambroxol chewable tablet
Prescription:
Cefetamet Pivoxil Hydrochloride 100g
Ambroxol hydrochloride 60g
Sucrose 122g
Micropowder silica gel 15g
10% starch slurry 30ml
Essence 2ml
Magnesium stearate 3g
Make 1000
Preparation technology: take by weighing Cefetamet Pivoxil Hydrochloride, ambroxol hydrochloride, sucrose respectively by above-mentioned prescription, pulverize the back and cross 80 eye mesh screens, mix homogeneously adds 10% starch slurry system soft material, the wet grain of the 20 mesh sieve systems of crossing, 50 ℃ of dryings 3 hours, add micropowder silica gel, magnesium stearate is crossed 18 mesh sieve granulate, sprays into essence, mix homogeneously, the heavily about 0.3g of tabletting, sheet.
Embodiment 11: the preparation of cefixime Ambroxol Hydrochloride Oral Solution
Prescription:
Cefixime 100g
Ambroxol hydrochloride 60g
Glycerol 300g
Water for injection adds to 1000ml
Make 1000ml altogether
Preparation technology: take by weighing each supplementary material respectively by above-mentioned prescription, ambroxol hydrochloride is dissolved in the 350ml water for injection, the dissolving back adds cefixime, stirring makes suspendible, adds glycerol again, adds the injection water after stirring evenly to 1000ml, be sub-packed in the plastic bottle every bottle of 50ml.
Embodiment 12: the preparation of cefixime ambroxol dry suspension
Prescription:
Cefixime 100.0g
Ambroxol hydrochloride 60.0g
Sucrose 840.0g
Make 1000g altogether
Preparation technology: take by weighing cefixime, ambroxol hydrochloride and sucrose by above-mentioned prescription, pulverize separately is crossed mix homogeneously behind 60 mesh sieves, is sub-packed in the packaging bag every bag of 1g.
Embodiment 13: the preparation of Ro 15-8074/001 ambroxol injection
Prescription:
Ro 15-8074/001 60g
Ambroxol hydrochloride 60g
Make 1000
Preparation technology: under the gnotobasis, (refining methanol is through the aseptic washing of 95% ethanol with the Ro 15-8074/001 aseptic powder by above-mentioned prescription, dry gained) and the fully mixing in aseptic Aluminum Drum of ambroxol hydrochloride aseptic powder, be distributed into 1000, every 0.12g seals with butyl rubber bung.
Embodiment 14: the preparation of Ro 15-8074/001 ambroxol freeze-dried powder
Prescription:
Ro 15-8074/001 60g
Ambroxol hydrochloride 60g
Make 1000
Preparation technology: by above-mentioned prescription Ro 15-8074/001, ambroxol hydrochloride are added injection water 1000ml dissolving, through aseptic filtration, be sub-packed in the 5ml cillin bottle, every dress 1ml put in the freeze drying box lyophilizing 26 hours, and tamponade under the vacuum is taken out and added a cover aluminium lid, promptly.Said preparation can be made intravenous injection, and intravenous drip or intramuscular injection are used.
Embodiment 15: contrast test
Experimental technique: select respiratory tract disease inpatient 20 examples to be divided into two groups randomly, matched group 8 examples, experimental group 12 examples.The every routine patient of matched group all oral cefixime sheet (containing cefixime 0.1g) every day 2 times before inspection, experimental group is taken cefixime ambroxol sheet (containing cefixime 0.1g, ambroxol hydrochloride 0.06g) every day 2 times.Collect after 3 days and middle cefixime of measurement bronchoalveolar lavage fluid (BALF) and proteic concentration, calculate both ratios.
Experimental result: (0.037 ± 0.014mg/L) than matched group (0.022 ± 0.011mg/L) high (P＜0.05) for the content of cefixime among the experimental group BALF; Cefixime content and protein content ratio 0.10 also are higher than 0.04 of matched group among the experimental group BALF, P＜0.05.And protein content there was no significant difference (P＜0.05) among two groups cefixime plasma concentration and the BALF.
Conclusion: use the experimental group and the matched group that uses the cefixime sheet of cefixime ambroxol sheet, the former cefixime concentration in lung more helps the treatment of pulmonary infection apparently higher than the latter.
Claims (8)
1, a kind of compound medicinal formulation for the treatment of pneumonia infection disease is characterized in that it mainly is to be made by 1: 1～20 weight proportion by ambroxol hydrochloride and cephalo-type antibiotics active component.
2, compound medicinal formulation according to claim 1 is characterized in that described cephalo-type antibiotics selects cefixime, Ro 15-8074/001 or Cefetamet Pivoxil Hydrochloride for use.
3, compound medicinal formulation according to claim 1, the weight proportion that it is characterized in that described ambroxol hydrochloride and cefixime is 1: 1～10.
4, compound medicinal formulation according to claim 1, the weight proportion that it is characterized in that described ambroxol hydrochloride and Ro 15-8074/001 is 1: 1～5.
5, compound medicinal formulation according to claim 1, the weight proportion that it is characterized in that described ambroxol hydrochloride and Cefetamet Pivoxil Hydrochloride is 1: 1～8.
6, according to claim 1,3,4,5 each described compound medicinal formulations, it is characterized in that described compound medicinal formulation comprises peroral dosage forms such as tablet, dispersible tablet, chewable tablet, capsule, granule, oral liquid, dry suspension, and various injection, injectable sterile powder, freeze-dried powder etc.
7, compound medicinal formulation according to claim 6 is characterized in that described preparation comprises adjuvant necessary on the galenic pharmacy, and the adjuvant of described necessity comprises the diluent of tablet, binding agent, disintegrating agent, lubricant, correctives, aromatic; The solvent of oral liquid, stabilizing agent, acid-base modifier; The cosolvent of injection, antioxidant, acid-base modifier.
8, a kind of compound medicinal formulation for the treatment of pneumonia infection disease is characterized in that it is that active component and adjuvant are made various dosage forms by the universal method on the galenic pharmacy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410081382 CN1650868A (en) | 2004-12-02 | 2004-12-02 | Compound medicinal preparation for treating pneumonia infection disease and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410081382 CN1650868A (en) | 2004-12-02 | 2004-12-02 | Compound medicinal preparation for treating pneumonia infection disease and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1650868A true CN1650868A (en) | 2005-08-10 |
Family
ID=34869144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410081382 Pending CN1650868A (en) | 2004-12-02 | 2004-12-02 | Compound medicinal preparation for treating pneumonia infection disease and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1650868A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD4093B1 (en) * | 2004-05-03 | 2011-02-28 | Boehringer Ingelheim International Gmbh | Use of topical pharmaceutical composition containing ambroxol |
| WO2011139255A2 (en) | 2010-05-04 | 2011-11-10 | Mahmut Bilgic | Pharmaceutical compositions comprising cefetamet |
| CN101491501B (en) * | 2008-01-24 | 2012-09-26 | 沈阳华泰药物研究有限公司 | Preparation method of ambroxol for injection |
| CN104606166A (en) * | 2015-02-04 | 2015-05-13 | 上海华源安徽仁济制药有限公司 | Compound cefalexin capsule and preparation method thereof |
| CN110302202A (en) * | 2016-09-30 | 2019-10-08 | 华北制药河北华民药业有限责任公司 | The method for preparing cefamandole nafate for injection powder injection formulation |
-
2004
- 2004-12-02 CN CN 200410081382 patent/CN1650868A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD4093B1 (en) * | 2004-05-03 | 2011-02-28 | Boehringer Ingelheim International Gmbh | Use of topical pharmaceutical composition containing ambroxol |
| CN101491501B (en) * | 2008-01-24 | 2012-09-26 | 沈阳华泰药物研究有限公司 | Preparation method of ambroxol for injection |
| WO2011139255A2 (en) | 2010-05-04 | 2011-11-10 | Mahmut Bilgic | Pharmaceutical compositions comprising cefetamet |
| CN104606166A (en) * | 2015-02-04 | 2015-05-13 | 上海华源安徽仁济制药有限公司 | Compound cefalexin capsule and preparation method thereof |
| CN110302202A (en) * | 2016-09-30 | 2019-10-08 | 华北制药河北华民药业有限责任公司 | The method for preparing cefamandole nafate for injection powder injection formulation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1297274C (en) | Medical composition | |
| CN1155388C (en) | Orally administrable solid ribavirin dosafe forms and process for making them | |
| CN1105240A (en) | Pharmaceutical composition | |
| CN1205931C (en) | Pharmaceutical agent comprising benzamide derivative as active ingredient | |
| CN1650868A (en) | Compound medicinal preparation for treating pneumonia infection disease and its preparation method | |
| CN1147295C (en) | Rapid release tablet comprising tolfenamic acid or a pharmaceutically acceptable salt thereof | |
| CN1864684A (en) | Lyophilized powder injection of doxofylline and preparation method thereof | |
| CN101032479A (en) | Medicine for treating gastrointestinal ulceration and its preparing process | |
| CN1954808A (en) | High dose Ambroxol hydrochloride freeze-dried preparation and preparation method | |
| CN101041024A (en) | Medicinal composition for treating tuberculosis and its preparing process | |
| CN1264520C (en) | Enteric-coated azithromycin preparation and its preparing process | |
| CN1939305A (en) | Cephalofruxin ester liposome, its preparation and medicinal composition containing it | |
| CN1612873A (en) | 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione and pharmaceutical composition containing the compound | |
| CN1268340C (en) | Pharmaceutical composition containing fused indole compound | |
| CN1615844A (en) | Development of micro particle silybum marianum preparation | |
| CN1799543A (en) | Telmisartan dispersible tablet and its preparation method | |
| CN100336511C (en) | Release-controlled oral Roxithromycin formulation | |
| CN101049312A (en) | Composition of medication, preparation method and application | |
| CN1915216A (en) | New usage of tandospirone and its derivative, and composition containing tandospirone | |
| CN1237965C (en) | Oral disintegrating tablet of bambuterol hydrochloride and its preparation method | |
| CN1823808A (en) | Clindamycin palmitate hydrochloride dispersion tablet and its preparation method | |
| CN100346787C (en) | Composite medicine containing flucloxacillin magnesium and amoxicillin sodium | |
| CN1303086C (en) | Compound of dual functional esterified prodrug of Cefetamet, and oral preparation | |
| CN100340239C (en) | Andrographolide dispersing tablets | |
| CN1943561A (en) | Oral disintegration tablet of prulifloxacin and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |